Citius Pharmaceuticals
CTXR
6 hedge funds and large institutions have $2.17M invested in Citius Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
56,821% more capital inflows, than outflows
Capital inflows: $1.71M | Capital outflows: $3K
4.56% more ownership
Funds ownership: 2.45% → 7.01% (+4.6%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55.2K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$51.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$14.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Delpha Capital Management
New York
|
-$3K |
CTXR Hedge Fund Activity: Q1 2018 in Review
6 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2018, worth a combined $2.17M — up 134% from $926K a quarter earlier.
Fund positioning in CTXR was balanced in Q1 2018: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $1.59M. The largest seller was Delpha Capital Management, exiting entirely with an estimated $3K sold.
- 6 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2018, down from 7 in Q4 2017.
- Funds reported $2.17M of Citius Pharmaceuticals stock for Q1 2018, up 134% quarter-over-quarter.
- 1 fund opened new Citius Pharmaceuticals positions in Q1 2018 and 1 closed out, a net change of 0 holders.
- The largest Citius Pharmaceuticals buyer in Q1 2018 was Sabby Management, an estimated $1.59M added.
- The largest Citius Pharmaceuticals seller in Q1 2018 was Delpha Capital Management, an estimated $3K sold.
Based on aggregated 13F filings for Q1 2018.